Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation - TheNote.app

GSK press releases

Follow

Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

Interim analysis of the HIV Prevention Trials Network (HPTN) 083 study.

https://www.gsk.com/en-gb/media/press-releases/global-hiv-prevention-study-to-stop-early-after-viiv-healthcare-s-long-acting-injectable-shows-higher-efficacy-than-daily-oral-prep/ gsk.com

RSS Hunter • May 18, 2020